VERTEX PHARMACEUTICALS INC / MA Total Liabilities and Equity
VERTEX PHARMACEUTICALS INC / MA (VRTX) had Total Liabilities and Equity of $27.42 billion as of 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Balance Sheet
us-gaap:LiabilitiesAndStockholdersEquity · last filed 2026-08-04
- 2026-06-30: Liabilities and Equity $27.42B.
- 2026-03-31: Liabilities and Equity $26.48B.
- 2025-12-31: Liabilities and Equity $25.64B.
- 2025-09-30: Liabilities and Equity $24.86B.
| Period end | Liabilities and Equity | Liabilities and Equity as first filed |
|---|---|---|
| 2026-06-30 | $27.42B 10-Q · filed 2026-08-04 | |
| 2026-03-31 | $26.48B 10-Q · filed 2026-05-05 | |
| 2025-12-31 | $25.64B 10-Q · filed 2026-08-04 | |
| 2025-09-30 | $24.86B 10-Q · filed 2025-11-04 | |
| 2025-06-30 | $24.04B 10-Q · filed 2025-08-05 | |
| 2025-03-31 | $22.88B 10-Q · filed 2025-05-06 | |
| 2024-12-31 | $22.53B 10-K · filed 2026-02-13 | |
| 2024-09-30 | $22.24B 10-Q · filed 2024-11-05 | |
| 2024-06-30 | $20.13B 10-Q · filed 2024-08-02 | |
| 2024-03-31 | $23.92B 10-Q · filed 2024-05-07 | |
| 2023-12-31 | $22.73B 10-K · filed 2025-02-13 | |
| 2023-09-30 | $21.73B 10-Q · filed 2023-11-07 | |
| 2023-06-30 | $20.35B 10-Q · filed 2023-08-02 | |
| 2023-03-31 | $18.97B 10-Q · filed 2023-05-02 | |
| 2022-12-31 | $18.15B 10-K · filed 2024-02-15 | |
| 2022-09-30 | $16.71B 10-Q · filed 2022-10-28 | |
| 2022-06-30 | $15.58B 10-Q · filed 2022-08-05 | |
| 2022-03-31 | $14.26B 10-Q · filed 2022-05-06 | |
| 2021-12-31 | $13.43B 10-K · filed 2023-02-10 | |
| 2021-09-30 | $12.62B 10-Q · filed 2021-11-03 | |
| 2021-06-30 | $12.22B 10-Q · filed 2021-07-30 | |
| 2021-03-31 | $12.12B 10-Q · filed 2021-04-30 | |
| 2020-12-31 | $11.75B 10-K · filed 2022-02-09 | $11.75B 10-K · filed 2021-02-11 |
| 2020-09-30 | $11.30B 10-Q · filed 2020-10-30 | |
| 2020-06-30 | $10.22B 10-Q · filed 2020-07-31 | |
| 2020-03-31 | $8.89B 10-Q · filed 2020-05-01 | |
| 2019-12-31 | $8.32B 10-K · filed 2021-02-11 | |
| 2019-09-30 | $7.51B 10-Q · filed 2019-10-31 | |
| 2019-06-30 | $7.03B 10-Q · filed 2019-08-01 | |
| 2019-03-31 | $6.54B 10-Q · filed 2019-05-01 | |
| 2019-01-01 | $6.26B 10-K · filed 2020-02-13 | |
| 2018-12-31 | $6.25B 10-K · filed 2020-02-13 | |
| 2018-09-30 | $4.62B 10-Q · filed 2018-10-25 | |
| 2018-06-30 | $4.34B 10-Q · filed 2018-07-26 | |
| 2018-03-31 | $3.95B 10-Q · filed 2018-04-27 | |
| 2018-01-01 | $3.56B 10-K · filed 2019-02-13 | |
| 2017-12-31 | $3.55B 10-K · filed 2019-02-13 | |
| 2017-09-30 | $3.20B 10-Q · filed 2017-10-30 | |
| 2017-06-30 | $3.29B 10-Q · filed 2017-07-28 | |
| 2017-03-31 | $2.95B 10-Q · filed 2017-04-28 | |
| 2016-12-31 | $2.90B 10-K · filed 2018-02-15 | |
| 2016-09-30 | $2.61B 10-Q · filed 2016-10-31 | |
| 2016-06-30 | $2.55B 10-Q · filed 2016-08-01 | |
| 2016-03-31 | $2.49B 10-Q · filed 2016-05-03 | |
| 2015-12-31 | $2.50B 10-K · filed 2017-02-23 | $2.50B 10-K · filed 2016-02-16 |
| 2015-09-30 | $2.43B 10-Q · filed 2015-10-30 | |
| 2015-06-30 | $2.37B 10-Q · filed 2015-08-04 | |
| 2015-03-31 | $2.17B 10-Q · filed 2015-05-04 | |
| 2014-12-31 | $2.33B 10-K · filed 2016-02-16 | |
| 2014-09-30 | $2.41B 10-Q · filed 2014-11-06 | |
| 2014-06-30 | $2.12B 10-Q · filed 2014-07-31 | |
| 2014-03-31 | $2.20B 10-Q · filed 2014-05-05 | |
| 2013-12-31 | $2.32B 10-K · filed 2015-02-13 | |
| 2013-09-30 | $2.58B 10-Q · filed 2013-11-07 | |
| 2013-06-30 | $2.58B 10-Q · filed 2013-08-02 | |
| 2013-03-31 | $2.39B 10-Q · filed 2013-05-08 | |
| 2012-12-31 | $2.76B 10-K · filed 2014-02-11 | |
| 2012-09-30 | $2.72B 10-Q · filed 2012-11-06 | |
| 2012-06-30 | $2.60B 10-Q · filed 2012-08-08 | |
| 2012-03-31 | $2.35B 10-Q · filed 2012-05-10 | |
| 2011-12-31 | $2.20B 10-K · filed 2013-03-01 | |
| 2011-09-30 | $2.09B 10-Q · filed 2011-11-03 | |
| 2011-06-30 | $1.76B 10-Q · filed 2011-08-09 | |
| 2011-03-31 | $1.54B 10-Q · filed 2011-05-06 | |
| 2010-12-31 | $1.73B 10-K · filed 2012-02-22 | |
| 2010-09-30 | $1.89B 10-Q · filed 2010-10-28 | |
| 2010-06-30 | $1.65B 10-Q · filed 2010-08-03 | |
| 2010-03-31 | $1.77B 10-Q · filed 2010-05-03 | |
| 2009-12-31 | $1.96B 10-K · filed 2011-02-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |